You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 28, 2024

Regulatory Exclusivity Expiring in 2027


✉ Email this page to a colleague

« Back to Dashboard


Drugs with Regulatory Exclusivity Expiring in 2027

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Exclusivity Expiration Patented / Exclusive Use
Ucb Inc FINTEPLA fenfluramine hydrochloride SOLUTION;ORAL 212102-001 Jun 25, 2020 RX Yes Yes ⤷  Sign Up PEDIATRIC EXCLUSIVITY
Polarean XENOVIEW xenon xe-129 hyperpolarized GAS;INHALATION 214375-001 Dec 23, 2022 RX Yes Yes ⤷  Sign Up NEW CHEMICAL ENTITY
Gilead Sciences Inc SUNLENCA lenacapavir sodium SOLUTION;SUBCUTANEOUS 215973-001 Dec 22, 2022 RX Yes Yes ⤷  Sign Up NEW CHEMICAL ENTITY
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Exclusivity Expiration >Patented / Exclusive Use

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.